PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Key Panelists in 2nd Oncology Partnering Event on February 25-26, 2013 in Las Vegas - Panel Discussion on ‘Innovative Partnering & Deal-making in Oncology’ Features Panelists from AstraZeneca, Amgen, Endocyte and Pfizer at 2nd Oncology Partnering & Deal-Making Conference (Feb 25-26, 2013 in Las Vegas) - GTCbio.com
Key Panelists in 2nd Oncology Partnering Event on February 25-26, 2013 in Las Vegas

 

NewswireToday - /newswire/ - Las Vegas, NV, United States, 2012/11/20 - Panel Discussion on ‘Innovative Partnering & Deal-making in Oncology’ Features Panelists from AstraZeneca, Amgen, Endocyte and Pfizer at 2nd Oncology Partnering & Deal-Making Conference (Feb 25-26, 2013 in Las Vegas) - GTCbio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Panel Participants include Timothy Herpin, Vice President at AstraZeneca; Elizabeth Bachert, Senior Director at Pfizer; Matthew Call, Vice President at Endocyte; and Ji Li, Executive Director at Amgen.

Panel discussion topics include:

- Rationale driving key deals in 2012 and continued trends into 2013
- Aligning deal structures with corporate strategic goals
- How the heightened risk environment is affecting deals
- Pros and cons of regional deal-making
- At what stage or what type of data makes the asset most attractive to a buyer?
- How do you find and decide who a good partner is?
- What determines the value of the deal?
- What preparation should you do before the deal?
- What kind of terms besides financials should you think about?
- What are the criteria to attract investors?

This event is a partnership and business development conference that offers participants the opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations and learn about relevant issues in oncology that will affect the industry. Experts in the field of oncology will present on the latest discoveries, novel technologies, business development trends, markets, partnership opportunities, alliance management, and regulatory guidance. There will be a mix of presentations and interactive panel discussions so join your business development colleagues at this unique partnering forum!

Presentations to be given by top executives from the following companies: Amgen, AstraZeneca, Bayer, Eli Lilly, Merck KGaA, Pfizer, Astellas, Dendreon, Endocyte, Astex Pharmaceuticals, Array BioPharma, Aveo Pharmaceuticals, Aragon Pharmaceuticals, Blueprint Medicines, Forma Therapeutics, MacroGenics, MedImmune, Tracon Pharma, and many more.

This conference is part of GTC’s larger 2nd Novel Cancer Therapeutics Summit, which consists of two other parallel conferences called the 4th Cancer Targets & Therapeutics and 3rd Ubiquitin Research & Drug Discovery.

For more information, please visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Key Panelists in 2nd Oncology Partnering Event on February 25-26, 2013 in Las Vegas

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Kristen Starkey - GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)